Abstract-Preeclampsia-related morbidity and mortality is rising predominantly because of delayed identification of patients at risk for preeclampsia with severe features and associated complications. This study explored the association between angiogenic markers (sFlt1 [soluble fms-like tyrosine kinase-1]) and PlGF [placental growth factor]) and preeclampsia-related peripartum complications. Normotensive women or those with hypertensive disorders of pregnancy were enrolled. Blood samples were collected within 96 hours before delivery, and angiogenic markers were measured on an automated platform. Our study included 681 women, 375 of which had hypertensive disorders. Of these, 127 (33.9%) had severe preeclampsia, and 71.4% were black. Compared with normotensive women, women with severe preeclampsia had higher levels of sFlt1 (9372.5 versus 2857.0 pg/mL; P<0.0001), lower PlGF (51.0 versus 212.0 pg/mL; P<0.0001), and a high sFlt1/PlGF (212.0 versus 14.0; all P<0.0001). A similar trend in sFlt1, PlGF, and sFlt1/PlGF was found in those women with complications secondary to preeclampsia (all P<0.001). The highest tertile of sFlt1/PlGF was strongly associated with severe preeclampsia in a multivariable analysis. Among patients with a hypertensive disorder of pregnancy, 340 (90.7%) developed postpartum hypertension, of which 50.4% had mild, and 40.3% had severe postpartum hypertension. The sFlt1/PlGF ratio was significantly higher for severe and mild postpartum hypertension compared with women with normal postpartum blood pressures (73.5, 46.0, and 13.0, respectively; P values<0.0001). Furthermore, the highest tertile of antepartum sFlt1/PlGF was associated with postpartum hypertension (P=0.004). This study demonstrates a significant association between an abnormal angiogenic profile before delivery and severe preeclampsia and peripartum complications. (Hypertension. 2019;73:868-877.
H ypertensive disorders of pregnancy (HDP) complicate about 7% and 9% of pregnancies worldwide. Preeclampsia is the most common HDP and one of the leading causes of maternal and fetal death worldwide. 1 Maternal morbidity related to preeclampsia can occur in the antepartum, intrapartum, or postpartum period. These complications include but are not restricted to increased risk of abruption, bleeding, intensive care admission, severe hypertension, intrauterine growth restriction, postpartum hypertension (PPHTN), readmission, and in severe cases, maternal death. 2 Furthermore, preeclampsia is a leading cause of premature delivery, which by itself can lead to significant neonatal morbidity and mortality. 3 The rates of morbidity and mortality are on the rise in United States, and this is even more striking among black women. 4, 5 Reviews of mortality data reveal that in many cases, death might have been averted if obstetric care providers had the ability to predict which patients will experience adverse outcomes. [6] [7] [8] Unfortunately, there is still no well-established method for risk assessment in the development or the severity of preeclampsia. Misinterpretation or failure to recognize worsening signs of preeclampsia can result in delayed diagnosis and treatment leading to increased morbidity and mortality. 6 We and others have shown an association between maternal adverse outcomes and angiogenic factor abnormalities (higher levels of antiangiogenic protein sFlt1 [soluble fms-like tyrosine kinase-1] and lower levels of proangiogenic protein PlGF [placental growth factor]). The ratio of sFlt1/ PlGF is related to diagnosis of preeclampsia, 9 eclampsia, adverse outcomes, maternal/fetal death, preterm delivery, 10, 11 and PPHTN. 12 However, most studies looking at the association with intrapartum and postpartum complications are done weeks before diagnosis.
The objective of this study was to determine the association between plasma levels of angiogenic markers assessed before delivery and preeclampsia-related peripartum morbidities which included diagnosis of preeclampsia with severe features, adverse maternal/fetal/neonatal outcomes and PPHTN. Furthermore, we set out to determine if angiogenic markers are associated with excessive resource utilization among these women and length of stay.
Methods
The authors declare that all supporting data are available within the article (and in the online-only Data Supplement).
Study Design
The study was approved by the Institutional Review Board at the University of Chicago (Institutional Review Board No. 14-0977), and all participants gave written informed consent before initiation of study procedures. All procedures followed were in accordance with institutional guidelines. Subjects were enrolled upon admission to the University of Chicago Family Birth Center between January 2015 and March 2017. Normotensive patients and patients with HDP were identified and consented on admission. Singleton pregnancies between 22 and 41 weeks were included. All consenting patients had a blood sample collected on admission and then every 3 days until delivery. If a patient was discharged, a predelivery sample was subsequently collected on readmission. This is a study of convenience, in which patients were approached for consenting and only patients who consented to have their blood drawn were enrolled.
Data Collection
Maternal data were abstracted from the electronic medical record and entered into a REDCap (Research Electronic Data Capture) database. Clinical data, including demographic data (age, race/ethnicity, parity, history of preterm birth or preeclampsia, maternal comorbidities), mode of delivery and gestational age at delivery, medication use (antihypertensives, magnesium, betamethasone), indication for delivery, highest blood pressures before delivery, severe features of preeclampsia (headache, visual symptoms, right upper quadrant/ epigastric pain, laboratory abnormalities), intensive care unit (ICU) admission, maternal complications, postpartum blood pressures, and any readmissions within 6 weeks were recorded. Neonatal outcome data were abstracted from both the maternal and fetal charts to ensure concordance. Neonatal data collected included birth weight, Appearance, Pulse, Grimace, Activity, and Respiration scores, neonatal ICU admission.
Diagnosis of HDP
The diagnoses of preeclampsia, severe preeclampsia, gestational hypertension, and chronic hypertension (cHTN) were based on American College of Obstetricians and Gynecologists criteria published in 2013. 2 All diagnoses were assessed by research personnel from the medical records and confirmed by 2 authors (J.L. Perdigao and S. Rana). PPHTN was defined as blood pressure ≥140/90 any time after delivery and within 6 weeks postpartum. There is no standard definition of PPHTN; however, previous papers have used similar definition. 13 For further explanation of definitions, see onlineonly Data Supplement.
Preeclampsia-Related Maternal Complications
Maternal complications were defined as the presence of hemolysis, elevated liver enzymes, low platelet count syndrome, elevated AST (aspartate aminotransferase) or ALT (alanine transaminase) to ≥80, platelet count ≤100×10 9 /L/µL, renal insufficiency (serum creatinine >1.1 mg/dL or a doubling of the baseline creatinine), transfusion of >4 units packed red blood cells, disseminated intravascular coagulation (defined clinically), abruption (clinical or pathological), eclampsia, cerebral hemorrhage, cardiomyopathy, pulmonary edema, or maternal death. All outcomes and clinical information were passively abstract from patients' charts.
Angiogenic Factors Estimation
Blood samples were centrifuged at 3000 revolutions/min for 10 minutes at 4°C and plasma was frozen at −80°C until the time of analysis. Only samples collected within 96 hours before delivery were analyzed. All coded samples were thawed once for analysis. Samples were analyzed for sFlt1 and PlGF on a fully automated BRAHMS KRYPTOR Compact Plus system (Thermo Fisher Scientific) according to the manufacturer's instructions.
14 The coefficient of variation for both assays were <5%. All measurements were performed after delivery on all patients. None of the treating physicians were aware of the assay results. The technician performing the analysis was blinded to the patients' final clinical diagnosis and outcomes.
Statistical Analysis
Continuous data are presented as mean±SD or median (interquartile range) depending on distribution and assessed with a t test or nonparametric equivalent. Normality was assessed with the Shapiro-Wilk test. Categorical data are presented as frequencies and proportions and assessed with a χ 2 or Fisher exact test, as appropriate. Univariate and multivariable logistic regression was used to assess the odds of experiencing preeclampsia with severe features or maternal complications, with odds ratios and 95% CIs reported. Sensitivity, specificity, positive predictive value, negative predictive value, and the area under the receiver operating curve are also reported for prediction of PPHTN.
Results

Demographics of Patients With Preeclampsia
Our cohort included 681 women, of whom 306 were normotensive, and 375 were diagnosed with HDP. The median age among all participants was 28 years old (interquartile range, 23-33), the median body mass index was 32.4 (interquartile range, 28.5, 38.4), the majority of patients were black (71.4%), 143 (21.0%) women were overweight (body mass index [BMI] between 25.0 and 29.9), and 437 (64.2% of patients were obese (BMI ≥30). Table 1 shows the demographics of all patients stratified by hypertensive status. Compared with normotensive women, women diagnosed with severe preeclampsia had significantly higher BMIs, a higher rate of history of prior preeclampsia, cHTN, and pregestational diabetes mellitus. These patients presented significantly more often with higher systolic and diastolic blood pressures (SBP; DBP), proteinuria, AST, ALT, creatinine, and lower platelet count (all P≤0.002). Figure [A] shows the proportion of different severe features. As expected, these women delivered at a significantly lower gestational age, lower birth weight, and had higher rates of premature delivery and cesarean section (all P<0.0001).
Demographics of Patients With PreeclampsiaRelated Maternal Complications
Of the 375 women who had diagnosis of HDP, 49 (13.1%) women experienced at least 1 complication (Table S1 ). Women with complications had a higher proportion of preeclampsia and severe preeclampsia. These women also had higher SBP and DBP and lab abnormalities (all P≤0.04). These women had earlier gestational ages of delivery, smaller birth weights, and experienced more cesarean section deliveries (all P<0.01). Hypertensive controls: patients with HDP without PE with severe features. ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; HC, hypertensive controls; HDP, hypertensive disorders of pregnancy; MAP, mean arterial pressure; NL, normal patients; PE, preeclampsia; PlGF, placental growth factor; SBP, systolic blood pressure; sFlt1, soluble fms-like tyrosine kinase; and sPE, PE with severe features. (Table 2) , there was significant association between higher levels of sFlt1/ PlGF and severe preeclampsia (P<0.0001). This association persisted when adjusting for baseline patient characteristics, including age, gestational age, parity, race, BMI, current smoking status, and history of cHTN or diabetes mellitus (odds ratio, 22.16; 95% CI, 9.77-50.28; P<0.0001).
Similarly, among women with HDP, patients with preeclampsia-related maternal complications had higher levels of sFlt1 (10010.0 versus 4044.0), lower PlGF (49.0 versus 99.0), and higher sFlt1/PlGF (301.0 versus 40.5; all P<0.001). When the cohort was divided into tertiles based levels of sFlt1/PlGF (Table 3) , there was significant association between maternal complications and higher levels of sFlt1/PlGF (P<0.0001). This remained unchanged when adjusting for baseline patient characteristics (odds ratio, 4.72, 95% CI, 1.59-14.00; P=0.01).
We observed that 85% of women with preterm preeclampsia (<34 weeks at delivery) had sFlt1/PlGF ≥85, and 94% had sFlt1/PlGF ≥38. Similar results were found among these patients with complications, with 88% of the patients with sFlt1/PlGF ≥85 and 92% of patients with sFlt1/PlGF ≥38. We analyzed the patients with preeclampsia with severe features and with low ratio (sFlt1/PlGF <38). We found that a majority of patients were diagnosed based on severe hypertension only (N=12), and among these 9 patients had cHTN (Table S2) .
Angiogenic Factors and Resource Utilization Among Women With HDP
Women with HDP were divided into sFlt1/PlGF ≥38 (n=173) and <38 (n=124) and evaluated for hospital resource utilization. Patients with a high sFlt1/PlGF had an increased use of magnesium for seizure prophylaxis, lower gestational age at delivery, higher rates of cesarean section, and maternal adverse outcomes. Though not statistically significant because of the small numbers of maternal ICU admissions, all women who required ICU admission were in the sFlt1/PlGF ≥38 (Table 4) . Patients in the sFlt1/PlGF ≥38 group also had higher neonatal ICU admissions, small for gestational age babies, and preterm delivery (both <37 and <34 weeks). These women were at higher risk of PPHTN and significantly increased length of stay.
Patients With PPHTN
Patients with HDP were divided into 3 groups based on their highest postpartum blood pressures-group A (postpartum SBP<140 and DBP<90; n=35), group B (postpartum SBP 140-159 or DBP 90-109; n=189) and group C (postpartum SBP ≥160 or DBP ≥110; n=151). Compared with group A, patients in group C delivered early, had higher antepartum SBP and DBP, as well as a higher antepartum antihypertensive and magnesium sulfate use (all P<0.001). These patients also had higher rates of preterm delivery (<37 weeks; P=0.002). Antepartum clinical characteristics of patients are shown in Table 5 . As expected, patients in group C also had higher SBP and DBP postpartum, were more likely to use antihypertensives postpartum, had increased time from delivery to discharge, and also a longer length of hospital stay, 
Angiogenic Factors and PPHTN
Levels of antepartum sFlt1 were higher among patients who had PPHTN compared with patients who were normotensive postpartum with lower levels of PlGF and higher sFlt1/ PlGF. Angiogenic protein levels among the 3 groups are shown in Table 5 . When the cohort was divided into tertiles of sFlt1/PlGF (Table 7) , there was a significant association between higher levels of sFlt1/PlGF and PPHTN (P=0.001). This association persisted when adjusting for baseline patient characteristics including age, gestational age, parity, race, BMI, current smoking status and history of cHTN, or diabetes mellitus (odds ratio, 10.18; 95% CI, 2.12-48.91; P=0.004). The sensitivity, specificity, positive, and negative predictive value of sFlt1/PlGF ≥38 and ≥85 are shown in Table S3 .
Discussion
In this study of women admitted with HDP, we were able to show that an abnormal antepartum angiogenic profile was associated with a diagnosis of severe preeclampsia, maternal complications, excessive resource utilization during hospitalization, increased risk of PPHTN, and length of stay. This study is one of the first focusing on a large cohort of black PPHTN was defined as any BP ≥140 or ≥90 after delivery up to 6 wk postpartum. ARF indicates acute renal failure; BP, blood pressure; BW, birthweight; DIC, disseminated intravascular coagulation; GA, gestational age; HELLP, hemolysis elevated liver enzymes and low platelets; ICU, intensive care unit; IUFD, intrauterine fetal death; LOS, length of stay; NICU, neonatal intensive care unit; PlGF, placental growth factor; PPHTN, postpartum hypertension; PTD, preterm delivery; and sFlt, soluble fms-like tyrosine kinase-1.
*Includes patients who experienced HELLP, transfusion of more than 4 units, transaminitis, thrombocytopenia, DIC, abruption, eclampsia, cerebral hemorrhage, ARF, cardiomyopathy, pulmonary edema or maternal death. Groups A, B, and C are divided based on postpartum blood pressures. All patients in this table experienced antepartum hypertension before delivery. ALT indicates alanine aminotransferase; ARF, acute renal failure; DBP, diastolic blood pressure; DIC, disseminated intravascular coagulation; HDP, hypertensive disorders of pregnancy; HELLP, hemolysis elevated liver enzymes and low platelets; HTN, hypertension; IUFD, intrauterine fetal death; PE, preeclampsia; PlGF, placental growth factor; SBP, systolic blood pressure; and sFlt, soluble fms-like tyrosine kinase-1.
*Comparison between groups A and B. †Comparison between groups A and C. ‡Reported only for patients who presented with a gestational age <34 wk on admission. §Other maternal complications include presence of any of the following: HELLP (n=6), transfusion of 4 units or more (n=2), DIC (n=1), eclampsia (n=1), abruption (n=2), cardiomyopathy (n=6), pulmonary edema (n=5) and cerebral hemorrhage (n=1).
women in an urban hospital in the United States evaluating peripartum complications. In addition, all analysis was done on an automated tabletop platform which makes assessment of these factors feasible for clinical use.
These findings have several implications. First, this study adds to the growing literature that profound angiogenic factor abnormalities exist in patients at risk for complications related to preeclampsia. Furthermore, we found that there is a significant association between these angiogenic markers antepartum and severe PPHTN, which can predispose to further maternal morbidity if not identified and treated adequately.
Complications arising from HDP are among the leading causes of preventable severe maternal morbidity and mortality. Early recognition and treatment of early warning signs were identified as a critical factor in reducing maternal morbidity and mortality in the data from the California PregnancyAssociated Mortality Review. 6 However, studies have shown that the clinical diagnostic criteria for preeclampsia lack both sensitivity and specificity, particularly for the development of preeclampsia-related adverse outcomes. 15, 16 Availability of a test which can reliably differentiate between patients who are at high risk of severe preeclampsia and associated complications versus those who are not will result in prompt treatment of mothers at risk. The biomarkers evaluated in this study serve as a promising trigger to be used in conjunction with the currently used clinical factors to stratify patients at risk of preeclampsia-related peripartum complications, including risk of severe PPHTN. These women could then be transferred to a higher level of care expeditiously for management based on established protocols, intensive surveillance, and appropriate maternal care as needed. This strategy could be especially useful and lifesaving in hospitals with limited resources and expertise.
Our study included a large number of black women at a tertiary care center. Assay analysis was done on an automated platform which can easily be implemented for future clinical use, adding to the strength of the study. Also, we had 2 clinicians review all of the diagnosis in the cohort to ascertain the correct diagnosis while being blinded to the angiogenic marker results. Despite this, our study is not without limitations. The majority of enrolled patients were black with a high BMI. This limits the generalizability of our data; however, prior studies of angiogenic factors have been done in populations comprised primarily of white women and have yielded similar results. 9, 10 Although blood samples were collected prospectively, much of the chart data was collected retrospectively and, therefore, could possibly introduce some bias. In addition, data were collected from a single center which limits the generalizability of our results. Patients were not followed beyond 6 weeks to confirm diagnosis of cHTN; therefore, it's possible that some patients designated as gestational hypertension or preeclampsia were in fact cHTN.
Perspectives
Although no randomized trial has resulted depicting the utility of angiogenic biomarkers in preeclampsia to show an improvement in outcomes, we think there is sufficient evidence that these markers should be used in assessment of patients with HDP. This can be lifesaving in regions of the world where maternal mortality is high and even in United States where mortality related to preeclampsia is on the rise.
